Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For COYA 302, which involves COYA 301 plus a fusion protein, we have entered into the DRL License Agreement with DRL whereby will in-license DRL's proposed Abatacept biosimilar to be used in the development and commercialization of COYA 302 in the United States, Canada, Mexico, South America, the European Union, the United Kingdom, and Japan.”
FILING10-K0001193125-26-107281cik 0001835022disclosed by COYA
“Both parties shall discuss in good faith and agree in writing on the terms of a commercial supply agreement for the purpose of supply of COYA 302 to Dr. Reddy's.”
FILING10-K0001193125-26-107281cik 0001835022disclosed by COYA
“In addition, we recognized revenue from Grifols of $9.1 million related to delivery of drug supplies and earned royalty, and $4.0 million from Dr. Reddy's related to an upfront fee from sublicensing olutasidenib.”
FILING10-K0001558370-25-002169cik 0001034842disclosed by RIGL
“In 2025, we announced that Alvotech had entered into a collaboration and license agreement with Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") to co-develop, manufacture and commercialize a biosimilar to Keytruda for global markets.”
FILING20-F0001898416-26-000004cik 0001898416disclosed by ALVO
“exclusive license of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, from Dr. Reddy's, who had”
FILING10-K0001213900-25-125331cik 0001851484disclosed by CTOR
“In September 2021, the Company entered into an asset purchase agreement with Dr. Reddy's and a license agreement with Eisai to acquire an exclusive license of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma.”
FILING10-K0001213900-25-125333cik 0001506251disclosed by CTXR
Watchlist prices, news filtered to it, and its next report on your desk.
DR Reddys Laboratories Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 11.54 · gapped above the open, never looked back. High/low 12.04 at 7:45 am ET, 11.54 at 3:30 pm ET.
DR Reddys Laboratories Ltd has 3 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either DR Reddys Laboratories Ltd’s own annual report or the counterparty’s, and carries the sentence that discloses it.
RDY (DR Reddys Laboratories Ltd) has 3 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ALVO +6.57%, in healthcare.